Samsung BioLogics, a biopharmaceutical unit of South Korea's Samsung Group, announced on July 4 that it has signed a contract manufacturing organization (CMO) contract worth US$55 million with Sun Pharmaceutical Industries, the largest drug maker in India.
At the signing ceremony held at the Samsung BioLogics headquarters in Songdo, Incheon, the two companies agreed that Samsung BioLogics will manufacture Tildrakizumab for Sun Pharma in the long term.
Sun Pharma jointly developed Tildrakizumab, a treatment of moderate-to-severe plaque psoriasis, with Germany’s Merck but acquired all the licenses for the product in 2014.
“Samsung Biologics is a globally renowned CMO. Through this partnership we will leverage Samsung’s manufacturing knowledge and world class quality systems to provide high quality products for the Tildrakizumab pipeline,” said Kirti Ganorkar, global head of the portfolio management and business development at Sun Pharma.